Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Assets (2017 - 2025)

Crinetics Pharmaceuticals has reported Non-Current Assets over the past 9 years, most recently at $77.9 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $77.9 million for Q4 2025, up 31.6% from a year ago — trailing twelve months through Dec 2025 was $295.3 million (up 22.68% YoY), and the annual figure for FY2025 was $77.9 million, up 31.6%.
  • Non-Current Assets for Q4 2025 was $77.9 million at Crinetics Pharmaceuticals, up from $74.8 million in the prior quarter.
  • Over the last five years, Non-Current Assets for CRNX hit a ceiling of $77.9 million in Q4 2025 and a floor of $5.0 million in Q1 2022.
  • Median Non-Current Assets over the past 5 years was $33.9 million (2023), compared with a mean of $36.3 million.
  • Biggest five-year swings in Non-Current Assets: decreased 14.44% in 2021 and later surged 903.16% in 2023.
  • Crinetics Pharmaceuticals' Non-Current Assets stood at $6.3 million in 2021, then increased by 11.07% to $7.0 million in 2022, then soared by 775.29% to $61.2 million in 2023, then dropped by 3.26% to $59.2 million in 2024, then skyrocketed by 31.6% to $77.9 million in 2025.
  • The last three reported values for Non-Current Assets were $77.9 million (Q4 2025), $74.8 million (Q3 2025), and $72.3 million (Q2 2025) per Business Quant data.